Tobira Therapeutics raises $31M to combat HIV

Princeton, N.J.’s Tobira Therapeutics, a newly formed biotech aiming to take on HIV, raised an impressive $31 million in a first funding round. Domain Associates and Frazier Healthcare Ventures led the round, joined by Montreux Equity Partners and Canaan Partners.

Profectus Bio wins $200K grant for HIV therapies

Baltimore, Md.-based Profectus BioSciences, a biotech developing new strategies to attack HIV, received a $200,000 small-business innovation grant from the National Institutes of Health to improve the effectiveness of anti-HIV antibodies. Last month, the company received a similar $300,000 grant (PDF link), just a few days after the company raised $3 million in a private placement.